cancers-logo

Journal Browser

Journal Browser

The Tumorigenesis Mechanism of Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 10 August 2026 | Viewed by 322

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA
Interests: breast cancer; drug; nanomedicine; antitumor

Special Issue Information

Dear Colleagues,

Breast cancer is a biologically diverse and clinically complex disease, representing one of the most prevalent malignancies worldwide. Its tumorigenesis involves a cascade of genetic mutations, epigenetic modifications, and dynamic interactions within the tumor microenvironment (TME). This Special Issue aims to consolidate current advances in understanding the molecular and cellular mechanisms that drive breast cancer initiation, progression, and metastasis.

Key oncogenic pathways such as PI3K/AKT/mTOR, MAPK/ERK, and Wnt/β-catenin are central to tumor cell proliferation, survival, and epithelial–mesenchymal transition (EMT). The influence of estrogen and mutations in BRCA1/2 and TP53 are highlighted as early triggers of tumorigenesis. A major focus of this issue is the immunosuppressive role of myeloid-derived suppressor cells (MDSCs), which facilitate immune evasion, angiogenesis, and premetastatic niche formation.

Innovative therapeutic strategies are explored for their potential to disrupt the immunosuppressive TME and enhance treatment efficacy. This Special Issue aims to bridge basic science and translational oncology, single-cell sequencing, spatial transcriptomics, or AI-driven drug discovery, promoting the development of biologics and precision therapies for breast cancer.

Scope and Topics of Interest

We welcome original research articles and comprehensive reviews that explore topics including but not limited to:

  • Molecular mechanisms of breast cancer initiation and progression;
  • Genomic instability and epigenetic regulation;
  • Hormonal signaling and estrogen-mediated oncogenesis;
  • Tumor microenvironment and stromal-immune interactions;
  • Role of MDSCs and other immunosuppressive cells;
  • Immune checkpoint pathways and resistance mechanisms;
  • Nanomedicine and targeted drug delivery systems;
  • Cell-based therapies and biologic innovations;
  • Translational models and preclinical validation strategies.

Dr. Swayam Prabha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • tumor microenvironment
  • myeloid-derived suppressor cells
  • immune evasion
  • premetastatic niche
  • epithelial–mesenchymal transition
  • PI3K/AKT/mTOR
  • MAPK/ERK
  • Wnt/β-catenin
  • BRCA1/2
  • TP53
  • estrogen signaling
  • targeted therapy
  • nanomedicine
  • biologics
  • precision oncology
  • translational research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop